The tweet was deleted by the author.
But we saved everything 🙂.
Bicara Therapeutics will announce its third quarter 2026 financial results and provide a business update on Monday, November 9.
The company will also host a conference call for investors at 8:30 AM ET, with details and webcast registration available through its official channels.
View post on X Loading...
Bicara Therapeutics recently initiated the FORTIFI-FLEX trial targeting HPV-negative head and neck cancer with a specific dosing regimen. The study marks a new step in the company’s clinical pipeline. Investors are expected to monitor updates on this and other programs during the upcoming results call.